CytoDyn (OTCMKTS:CYDY – Get Free Report) is projected to issue its Q1 2027 resultson Thursday, October 8th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Wednesday, October 14, 2026 at 9:30 AM ET.
CytoDyn Price Performance
CytoDyn stock opened at $0.20 on Tuesday. The stock has a fifty day moving average price of $0.20 and a two-hundred day moving average price of $0.26. CytoDyn has a 52-week low of $0.18 and a 52-week high of $0.40. The firm has a market capitalization of $293.17 million, a P/E ratio of -9.97 and a beta of 1.50.
About CytoDyn
CytoDyn Inc is a biotechnology company focused on the development of leronlimab, an investigational monoclonal antibody that targets CCR5, a receptor involved in immune-cell signaling and the movement of certain cells through the body. The company’s research has explored potential applications in infectious diseases, oncology and inflammatory conditions.
Leronlimab, also known as PRO 140, has been studied primarily as a potential treatment for HIV infection, including in combination with existing antiretroviral therapies.
Featured Articles
- Five stocks we like better than CytoDyn
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
